Related Experiment Videos
Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial
I M Bowler1, B Kelman, D Worthington
1Regional Paediatric Cystic Fibrosis Unit, St James's University Hospital, Leeds.
Insights
Nebulised amiloride did not improve overall respiratory function in cystic fibrosis patients during inpatient treatment. However, it may speed up recovery, warranting further investigation into its effect on treatment duration.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Clinical Trials
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting the lungs, leading to chronic respiratory infections and exacerbations.
- Standard inpatient treatment for CF exacerbations aims to improve respiratory function and reduce inflammation.
- Nebulised amiloride, a sodium channel inhibitor, has been explored for its potential to improve mucus hydration in CF.
Purpose of the Study:
- To evaluate the efficacy of adding nebulised amiloride to standard inpatient care for respiratory exacerbations in cystic fibrosis patients.
- To assess the impact of amiloride on key respiratory function parameters and recovery time.
Main Methods:
- A prospective, randomized, double-blind, placebo-controlled trial was conducted.
- Twenty-seven cystic fibrosis patients (mean age 12.8 years) participated across two UK hospitals.
- Patients received either nebulised amiloride or a placebo as an adjunct to standard treatment.
Main Results:
- Both amiloride and placebo groups showed improvements in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) over time.
- No significant differences in overall respiratory function were observed between the groups at study time points.
- The amiloride group demonstrated a significantly shorter time to reach peak FVC (4.2 vs. 7.6 days), but not peak FEV1.
Conclusions:
- Nebulised amiloride did not enhance overall respiratory function improvement in CF patients during inpatient treatment.
- A potential effect on the rate of FVC improvement suggests amiloride might influence treatment duration.
- Further research is recommended to confirm amiloride's impact on the speed of recovery and treatment length in CF exacerbations.
Objective:
To assess the benefit of nebulised amiloride added to the standard inpatient treatment of a respiratory exacerbation in cystic fibrosis.
Design:
Prospective, randomised, double blind, placebo controlled trial.
Subjects:
27 cystic fibrosis patients (mean age 12.8 years).
Setting:
Two hospitals in Leeds, UK.
Results:
Both forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) showed improvements over the course of treatment, although there was no difference in respiratory function between the two groups at any of three time periods during the study. The time to reach peak FVC was significantly reduced in the amiloride group (4.2 v 7.6 days; 95% CI 0.4 to 6.4 days), but not in the time to reach peak FEV1 (5.7 v 7.9 days; 95% CI -1.2 to 5.6 days).
Conclusions:
Amiloride did not result in a greater overall improvement in respiratory function. There was a suggestion that it may have an effect on the rate of improvement, and thus may possibly influence the duration of treatment. This hypothesis deserves further evaluation.